BASIC FACTS
DATE OF LAUNCH
16 FEBRUARY 1993
CATEGORY
EQUITY
TYPE
LARGE & MIDCAP
AUM*
Rs.2,380 crore
BENCHMARK
NIFTY LARGE MIDCAP 250
TOTAL RETURN INDEX
WHAT IT COSTS
NAV**
GROWTH OPTION
Rs.138.64
IDCW**
Rs.67.54
MINIMUM INVESTMENT
Rs.5,000
MINIMUM SIP AMOUNT
Rs.500
EXPENSE RATIO# (%)
2.09
EXIT LOAD
1% for redemption within 364 days
*AS ON 31 DEC 2023
**AS ON 9 JAN 2024
#AS ON 30 NOV 2023
FUND MANAGER
V. SRIVATSA
6 YEARS, 7 MONTHS
Recent portfolio changes
New entrants
Indo Count Industries (Nov),Caplin Point Laboratories, The Great Eastern Shipping Company (Dec).
Complete exits
ICICI Lombard General Insurance Comapny, NHPC, Suzlon Energy (Nov),eClerx Services, Eris Lifesciences (Dec).
Should You Buy
Earlier known as UTI Core Equity, this fund adopted the large- and mid-cap mandate in 2018. It follows a top-down approach to pick sectors with reasonable prospects, which are available below the mean valuations. For individual stock picks, the fund prefers sound businesses offering margin of safety. It shuns concentration and runs a fairly diversified portfolio. The fund exhibited erratic outcomes for many years till 2020. Since 2021, the fund’s return profile has visibly picked up. It must sustain this momentum in order to improve on its earlier patchy track record.
(Source: Value Research)
